Duality Biologics and BioNTech Highlight Interim Data from P-I/IIa Trial of BNT324/DB-1311 in Advanced Solid Tumors at ESMO Asia 2024
Shots:
- The P-I/IIa study assessed BNT324 (B7-H3 targeting ADC) in heavily pretreated patients (n=277) with advanced solid tumors, incl. SCLC, NSCLC, CRPC & SCCHN
- Study showed uORR of 32.4% & DCR of 82.4% in all evaluable patients (n=238). uORRs were 22% (non-squamous NSCLC), 16% (squamous NSCLC), 28% with 92% DCR, 7.2mos. median rPFS, & 94.7% 6mos. rPFS rate (CRPC), 75% (cervical), 25% (hepatocellular), 100% (HNSCC), 36.4% (melanoma) & 56.2% (ORR: 70.4% at 9mg/kg in those treated with immunotx. but not topoisomerase I inhibitors) with 89% DCR (SCLC)
- Other ongoing trials include P-I/II study of BNT325/DB-1305 + BNT327/PM8002 and P-I/II study of BNT324 + BNT327 in SCLC & NSCLC, planned for 2025
Ref: Duality Biologics | Image: BioNTech & Duality Biologics
Related News:- BioNTech and DualityBio Report the Initiation of P-III Trial for BNT323/DB-1303 to Treat Metastatic Breast Cancer
PharmaShots! Your go-to media platform for customized news ranging for multiple indications. For more information connect with us at connect@pharmashots.com
Click here to read the full press release
Disha is a content writer at PharmaShots. She is passionate and curious about recent updates and developments in MedTech and Pharma industry. She covers news related to clinical trial results and updates. She can be contacted at connect@pharmashots.com.
